{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:59:25Z","timestamp":1793120365867,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T00:00:00Z","timestamp":1620604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T00:00:00Z","timestamp":1620604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s11523-021-00817-2","type":"journal-article","created":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T06:08:49Z","timestamp":1620626929000},"page":"471-483","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Cardiovascular Toxicities of Antiangiogenic Tyrosine Kinase Inhibitors: A Retrospective, Pharmacovigilance Study"],"prefix":"10.1007","volume":"16","author":[{"given":"Adam","family":"Goldman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bomze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Dankner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Fourey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Boursi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Arad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5087-0464","authenticated-orcid":false,"given":"Elad","family":"Maor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,10]]},"reference":[{"key":"817_CR1","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1146\/annurev-pharmtox-011112-140341","volume":"53","author":"A Levitzki","year":"2013","unstructured":"Levitzki A. Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance. Annu Rev Pharmacol Toxicol. 2013;53:161\u201385.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"817_CR2","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1152\/physrev.1999.79.4.1283","volume":"79","author":"CH Heldin","year":"1999","unstructured":"Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 1999;79:1283\u2013316.","journal-title":"Physiol Rev"},{"key":"817_CR3","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nrd.2015.17","volume":"15","author":"N Ferrara","year":"2016","unstructured":"Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016;15:385\u2013403.","journal-title":"Nat Rev Drug Discov"},{"key":"817_CR4","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1056\/NEJMra1100265","volume":"375","author":"JJ Moslehi","year":"2016","unstructured":"Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med. 2016;375:1457\u201367.","journal-title":"N Engl J Med"},{"key":"817_CR5","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.jacc.2015.07.025","volume":"66","author":"W Li","year":"2015","unstructured":"Li W, Croce K, Steensma DP, McDermott DF, Ben-Yehuda O, Moslehi J. Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors. J Am Coll Cardiol. 2015;66:1160\u201378.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"817_CR6","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","volume":"17","author":"J Herrmann","year":"2020","unstructured":"Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020;17(8):474\u2013502.","journal-title":"Nat Rev Cardiol"},{"key":"817_CR7","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1177\/2047487318755193","volume":"25","author":"M Totzeck","year":"2018","unstructured":"Totzeck M, Mincu RI, Mrotzek S, Schadendorf D, Rassaf T. Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: a meta-analysis of approximately 29,000 cancer patients. Eur J Prev Cardiol. 2018;25:482\u201394.","journal-title":"Eur J Prev Cardiol"},{"key":"817_CR8","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/j.1582-4934.2005.tb00379.x","volume":"9","author":"AM Byrne","year":"2005","unstructured":"Byrne AM, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell survival functions of Vascular Endothelial Growth Factor (VEGF). J Cell Mol Med. 2005;9:777\u201394.","journal-title":"J Cell Mol Med"},{"key":"817_CR9","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","volume":"378","author":"BI Rini","year":"2011","unstructured":"Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378:1931\u20139.","journal-title":"Lancet"},{"key":"817_CR10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jchf.2012.09.001","volume":"1","author":"PS Hall","year":"2013","unstructured":"Hall PS, Harshman LC, Srinivas S, Witteles RM. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. JACC Hear Fail. 2013;1:72\u20138.","journal-title":"JACC Hear Fail"},{"key":"817_CR11","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.critrevonc.2012.12.006","volume":"87","author":"G Sonpavde","year":"2013","unstructured":"Sonpavde G, Je Y, Schutz F, Galsky MD, Paluri R, Rosenberg JE, et al. Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2013;87:80\u20139.","journal-title":"Crit Rev Oncol Hematol"},{"key":"817_CR12","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11523-020-00738-6","volume":"15","author":"E Raschi","year":"2020","unstructured":"Raschi E, Gatti M, Gelsomino F, Ardizzoni A, Poluzzi E, De Ponti F. Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: a clinical perspective from pharmacovigilance. Target Oncol. 2020;15:449\u201366.","journal-title":"Target Oncol"},{"key":"817_CR13","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","volume":"74","author":"JE Salem","year":"2019","unstructured":"Salem JE, Manouchehri A, Bretagne M, Lebrun-Vignes B, Groarke JD, Johnson DB, et al. Cardiovascular toxicities associated with ibrutinib. J Am Coll Cardiol. 2019;74:1667\u201378.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"817_CR14","doi-asserted-by":"publisher","first-page":"4803","DOI":"10.1038\/s41598-020-61571-5","volume":"10","author":"J Huang","year":"2020","unstructured":"Huang J, Meng L, Yang B, Sun S, Luo Z, Chen H. Safety profile of epidermal growth factor receptor tyrosine kinase inhibitors: a disproportionality analysis of FDA adverse event reporting system. Sci Rep. 2020;10(1):4803.","journal-title":"Sci Rep"},{"key":"817_CR15","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.eururo.2017.11.016","volume":"73","author":"T Powles","year":"2018","unstructured":"Powles T, Albiges L, Staehler M, Bensalah K, Dabestani S, Giles RH, et al. Updated European Association of Urology Guidelines: recommendations for the treatment of first-line metastatic clear cell renal cancer. Eur Urol. 2018;73:311\u20135.","journal-title":"Eur Urol"},{"key":"817_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers11091227","volume":"11","author":"JC Angulo","year":"2019","unstructured":"Angulo JC, Shapiro O. The changing therapeutic landscape of metastatic renal cancer. Cancers. 2019;11:1\u201313.","journal-title":"Cancers"},{"key":"817_CR17","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.numecd.2018.02.014","volume":"28","author":"E Raschi","year":"2018","unstructured":"Raschi E, Poluzzi E, Salvo F, Pariente A, De Ponti F, Marchesini G, et al. Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: what a clinician should know on disproportionality analysis of spontaneous reporting systems. Nutr Metab Cardiovasc Dis. 2018;28:533\u201342.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"817_CR18","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJW. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18:427\u201336.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"817_CR19","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/clpt.2013.24","volume":"93","author":"R Harpaz","year":"2013","unstructured":"Harpaz R, Dumouchel W, Lependu P, Bauer-Mehren A, Ryan P, Shah NH. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther. 2013;93:539\u201346.","journal-title":"Clin Pharmacol Ther"},{"key":"817_CR20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0962280211403604","volume":"22","author":"GN Nor\u00e9n","year":"2013","unstructured":"Nor\u00e9n GN, Hopstadius J, Bate A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res. 2013;22:57\u201369.","journal-title":"Stat Methods Med Res"},{"key":"817_CR21","doi-asserted-by":"publisher","first-page":"140043","DOI":"10.1038\/sdata.2014.43","volume":"1","author":"R Harpaz","year":"2014","unstructured":"Harpaz R, Odgers D, Gaskin G, Dumouchel W, Winnenburg R, Bodenreider O, et al. A time-indexed reference standard of adverse drug reactions. Sci Data. 2014;1:140043.","journal-title":"Sci Data"},{"key":"817_CR22","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19:1579\u201389.","journal-title":"Lancet Oncol"},{"issue":"8","key":"817_CR23","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41569-020-0347-2","volume":"17","author":"J Herrmann","year":"2020","unstructured":"Herrmann J. Vascular toxic effects of cancer therapies. Nat Rev Cardiol. 2020;17(8):503\u201322.","journal-title":"Nat Rev Cardiol"},{"key":"817_CR24","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ctrv.2016.12.002","volume":"53","author":"H Abdel-Qadir","year":"2017","unstructured":"Abdel-Qadir H, Ethier JL, Lee DS, Thavendiranathan P, Amir E. Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: a systematic review and meta-analysis. Cancer Treat Rev. 2017;53:120\u20137.","journal-title":"Cancer Treat Rev"},{"key":"817_CR25","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","volume":"370","author":"TF Chu","year":"2007","unstructured":"Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370:2011\u20139.","journal-title":"Lancet"},{"key":"817_CR26","doi-asserted-by":"publisher","first-page":"830.e17","DOI":"10.1016\/j.cjca.2017.03.002","volume":"33","author":"R Hatem","year":"2017","unstructured":"Hatem R, Bebawi E, Schampaert E. Potential sunitinib-induced coronary artery and aortic dissections. Can J Cardiol. 2017;33:830.e17-830.e18.","journal-title":"Can J Cardiol"},{"key":"817_CR27","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1093\/annonc\/mdp480","volume":"21","author":"J Edeline","year":"2009","unstructured":"Edeline J, Laguerre B, Rolland Y, Patard JJ. Aortic dissection in a patient treated by sunitinib for metastatic renal cell carcinoma. Ann Oncol. 2009;21:186\u20137.","journal-title":"Ann Oncol"},{"key":"817_CR28","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3109\/0284186X.2014.963887","volume":"54","author":"N Niwa","year":"2015","unstructured":"Niwa N, Nishiyama T, Ozu C, Yagi Y, Saito S. Acute aortic dissection in a patient with metastatic renal cell carcinoma treated with axitinib. Acta Oncol. 2015;54:567\u20138.","journal-title":"Acta Oncol"},{"key":"817_CR29","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1161\/CIRCULATIONAHA.116.025144","volume":"135","author":"Y Oshima","year":"2017","unstructured":"Oshima Y, Tanimoto T, Yuji K, Tojo A. Association between aortic dissection and systemic exposure of vascular endothelial growth factor pathway inhibitors in the Japanese Adverse Drug Event Report database. Circulation. 2017;135:815\u20137.","journal-title":"Circulation"},{"issue":"3","key":"817_CR30","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1179\/2295333715Y.0000000065","volume":"71","author":"D Kust","year":"2016","unstructured":"Kust D, Kruljac I, Peternac A\u0160, Ostoji\u0107 J, Prpi\u0107 M, \u010car\u017eavec D, et al. Pleural and pericardial effusions combined with ascites in a patient with severe sunitinib-induced hypothyroidism. Acta Clin Belg. 2016;71(3):175\u20137.","journal-title":"Acta Clin Belg"},{"key":"817_CR31","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3324\/haematol.2010.030494","volume":"96","author":"MT Krauth","year":"2011","unstructured":"Krauth MT, Herndlhofer S, Schmook MT, Mitterbauer-Hohendanner G, Schl\u00f6gl E, Valent P. Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily. Haematologica. 2011;96:163\u20136.","journal-title":"Haematologica"},{"key":"817_CR32","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s11523-009-0110-4","volume":"4","author":"K Kelly","year":"2009","unstructured":"Kelly K, Swords R, Mahalingam D, Padmanabhan S, Giles FJ. Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors. Target Oncol. 2009;4:99\u2013105.","journal-title":"Target Oncol"},{"key":"817_CR33","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","volume":"25","author":"A Quint\u00e1s-Cardama","year":"2007","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, O\u2019Brien S, Borthakur G, Bruzzi J, Munden R, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007;25:3908\u201314.","journal-title":"J Clin Oncol"},{"key":"817_CR34","doi-asserted-by":"publisher","first-page":"101966","DOI":"10.1016\/j.ctrv.2020.101966","volume":"84","author":"S Fogli","year":"2020","unstructured":"Fogli S, Porta C, Del Re M, Crucitta S, Gianfilippo G, Danesi R, et al. Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs. Cancer Treat Rev. 2020;84:101966.","journal-title":"Cancer Treat Rev"},{"key":"817_CR35","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1080\/02841860801978905","volume":"47","author":"JB Aragon-Ching","year":"2008","unstructured":"Aragon-Ching JB, Ning YM, Dahut WL. Acute aortic dissection in a hypertensive patient with prostate cancer undergoing chemotherapy containing bevacizumab. Acta Oncol. 2008;47:1600\u20131.","journal-title":"Acta Oncol"},{"key":"817_CR36","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1200\/JCO.2010.31.6067","volume":"29","author":"NM Hahn","year":"2011","unstructured":"Hahn NM, Stadler WM, Zon RT, Waterhouse D, Picus J, Nattam S, et al. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier oncology group GU 04\u201375. J Clin Oncol. 2011;29:1525\u201330.","journal-title":"J Clin Oncol"},{"key":"817_CR37","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1080\/14712598.2019.1594770","volume":"19","author":"G Pucci","year":"2019","unstructured":"Pucci G, Milan A, Paini A, Salvetti M, Cerasari A, Vaudo G. Acute blood pressure elevation associated with biological therapies for cancer: a focus on VEGF signaling pathway inhibitors. Expert Opin Biol Ther. 2019;19:433\u201342.","journal-title":"Expert Opin Biol Ther"},{"key":"817_CR38","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2165\/11597600-000000000-00000","volume":"35","author":"BK Shamloo","year":"2012","unstructured":"Shamloo BK, Chhabra P, Freedman AN, Potosky A, Malin J, Smith SW. Novel adverse events of bevacizumab in the US FDA adverse event reporting system database: a disproportionality analysis. Drug Saf. 2012;35:507\u201318.","journal-title":"Drug Saf"},{"key":"817_CR39","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.neurol.2015.03.010","volume":"171","author":"C Bonnet","year":"2015","unstructured":"Bonnet C, Sibon I. Potential role of anti-VEGF targeted therapies in cervical artery dissection: a case report. Rev Neurol. 2015;171:677\u20139.","journal-title":"Rev Neurol"},{"key":"817_CR40","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1002\/cncr.26429","volume":"118","author":"AM Molina","year":"2012","unstructured":"Molina AM, Feldman DR, Voss MH, Ginsberg MS, Baum MS, Brocks DR, et al. Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2012;118:1868\u201376.","journal-title":"Cancer"},{"key":"817_CR41","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"7","author":"M Schlumberger","year":"2015","unstructured":"Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;7:621\u201351.","journal-title":"N Engl J Med"},{"key":"817_CR42","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1111\/bcp.13693","volume":"84","author":"J Mah\u00e9","year":"2018","unstructured":"Mah\u00e9 J, de Campaigno EP, Chen\u00e9 A-L, Montastruc J-L, Despas F, Jolliet P. Pleural adverse drugs reactions and protein kinase inhibitors: identification of suspicious targets by disproportionality analysis from VigiBase. Br J Clin Pharmacol. 2018;84:2373\u201383.","journal-title":"Br J Clin Pharmacol"},{"key":"817_CR43","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1111\/bcp.13238","volume":"83","author":"E Patras de Campaigno","year":"2017","unstructured":"Patras de Campaigno E, Bondon-Guitton E, Laurent G, Montastruc F, Montastruc J-L, Lapeyre-Mestre M, et al. Identification of cellular targets involved in cardiac failure caused by PKI in oncology: an approach combining pharmacovigilance and pharmacodynamics. Br J Clin Pharmacol. 2017;83:1544\u201355.","journal-title":"Br J Clin Pharmacol"},{"key":"817_CR44","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SAW. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29:385\u201396.","journal-title":"Drug Saf"},{"key":"817_CR45","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1001\/jama.288.13.1588","volume":"288","author":"B B\u00e9gaud","year":"2002","unstructured":"B\u00e9gaud B, Martin K, Haramburu F, Moore N. Rates of spontaneous reporting of adverse drug reactions in France. J Am Med Assoc. 2002;288:1588.","journal-title":"J Am Med Assoc"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-021-00817-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-021-00817-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-021-00817-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T09:03:38Z","timestamp":1675328618000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-021-00817-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,10]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["817"],"URL":"https:\/\/doi.org\/10.1007\/s11523-021-00817-2","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,10]]},"assertion":[{"value":"23 April 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"AG, DB, RD, DF, BB, MA, and EM declare that they have no conflicts of interest that might be relevant to the contents of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The FAERS is a publicly available and anonymized database.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"A.G. and D.B. conceived the idea. All authors contributed to the design of the study. A.G. and D.B. acquired the data for the study and performed the analyses. E.M. supervised the study. A.G. wrote the manuscript. All authors interpreted the results and made manuscript revisions. All authors have read and agreed to the published version of the manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Since the FAERS is a publicly available and anonymized database, Institutional review board approval and informed consent were waived.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}